Beyond ACE2 downregulation: daphnetin as a multi-target agent for COVID-19 and rheumatic comorbidities.
Abstract
The continuous emergence of SARS-CoV-2 variants (e.g., JN.1, KP.3) and the significantly elevated risk of severe COVID-19 in patients with rheumatic autoimmune diseases highlight an urgent unmet clinical need for dual-targeted therapeutics. Daphnetin (7,8-dihydroxycoumarin), a natural coumarin compound with a long history of clinical use in China, prevents SARS-CoV-2 infection by downregulating the viral entry receptor ACE2 through inhibition of HIF-1α and JAK2/STAT3 signaling. This review synthesizes the pleiotropic pharmacological mechanisms of daphnetin, including anti-inflammatory (NF-κB, JAK/STAT, NLRP3), antioxidant (Nrf2/Keap1), immunomodulatory (Th17/Treg balance), and mitochondrial protective pathways. These pathways are critically involved in the pathogenesis of both severe COVID-19 and rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). We propose that daphnetin represents a novel "one agent, dual protection" strategy: it not only blocks viral entry by reducing ACE2 but also mitigates the hyperinflammatory and oxidative stress states that exacerbate both COVID-19 severity and rheumatic disease activity. Given its established safety, oral activity, and low cost, daphnetin is a promising candidate for clinical translation in high-risk comorbid populations. Key unresolved questions and future research directions are also discussed.